63 related articles for article (PubMed ID: 37016572)
1. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
[TBL] [Abstract][Full Text] [Related]
2. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
Liu M; Feng Y; Lu Y; Huang R; Zhang Y; Zhao Y; Mo R
Sci Adv; 2024 Mar; 10(11):eadk2444. PubMed ID: 38478602
[TBL] [Abstract][Full Text] [Related]
3. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
4. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
5. CpG-Based Nanovaccines for Cancer Immunotherapy.
Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
[TBL] [Abstract][Full Text] [Related]
6. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells.
Wang H; Wu X; Sun Y; Liu A; He Y; Xu Z; Lu Y; Zhan C
J Control Release; 2024 Apr; 368():208-218. PubMed ID: 38395156
[TBL] [Abstract][Full Text] [Related]
7. Antigen-Clustered Nanovaccine Achieves Long-Term Tumor Remission by Promoting B/CD 4 T Cell Crosstalk.
Li C; Clauson R; Bugada LF; Ke F; He B; Yu Z; Chen H; Jacobovitz B; Hu H; Chuikov P; Hill BD; Rizvi SM; Song Y; Sun K; Axenov P; Huynh D; Wang X; Garmire L; Lei YL; Grigorova I; Wen F; Cascalho M; Gao W; Sun D
ACS Nano; 2024 Apr; 18(13):9584-9604. PubMed ID: 38513119
[TBL] [Abstract][Full Text] [Related]
8. pH and ROS Responsiveness of Polymersome Nanovaccines for Antigen and Adjuvant Codelivery: An In Vitro and In Vivo Comparison.
Jäger E; Ilina O; Dölen Y; Valente M; van Dinther EAW; Jäger A; Figdor CG; Verdoes M
Biomacromolecules; 2024 Mar; 25(3):1749-1758. PubMed ID: 38236997
[TBL] [Abstract][Full Text] [Related]
9. Dual-Antigen-Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications.
Chen F; Zhang M; Yang F; Wang L; Liu J; Liu J; Pang Y
Small; 2024 Apr; 20(17):e2307748. PubMed ID: 38037689
[TBL] [Abstract][Full Text] [Related]
10. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.
Manna S; Maiti S; Shen J; Weiss A; Mulder E; Du W; Esser-Kahn AP
Biomaterials; 2023 May; 296():122062. PubMed ID: 36863071
[TBL] [Abstract][Full Text] [Related]
11. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
12. Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy.
Freitas R; Ferreira E; Miranda A; Ferreira D; Relvas-Santos M; Castro F; Santos B; Gonçalves M; Quintas S; Peixoto A; Palmeira C; Silva AMN; Santos LL; Oliveira MJ; Sarmento B; Ferreira JA
ACS Nano; 2024 Apr; 18(14):10088-10103. PubMed ID: 38535625
[TBL] [Abstract][Full Text] [Related]
13. Personalized Nanovaccines Enhance Lymph Node Accumulation and Reprogram the Tumor Microenvironment for Improved Photodynamic Immunotherapy.
Wang R; Li J; Wang X; Zhang Y; Zhu A; Feng K; Li J; Di L
Nano Lett; 2024 May; ():. PubMed ID: 38767889
[TBL] [Abstract][Full Text] [Related]
14. A Programmable Peptidic Hydrogel Adjuvant for Personalized Immunotherapy in Resected Stage Tumors.
Wu B; Liang J; Yang X; Fang Y; Kong N; Chen D; Wang H
J Am Chem Soc; 2024 Mar; 146(12):8585-8597. PubMed ID: 38478659
[TBL] [Abstract][Full Text] [Related]
15. Spatiotemporal Controllable Sono-Nanovaccines Driven by Free-Field Based Whole-Body Ultrasound for Personalized Cancer Therapy.
Wang Y; Li G; Su J; Liu Y; Zhang X; Zhang G; Wu Z; Li J; Zhang Y; Wang X; Yang Z; Wang R; Wang C; Wang L; Sun F; Zhao W; Wang X; Peng X; Shao K
Adv Sci (Weinh); 2024 Apr; 11(14):e2307920. PubMed ID: 38308196
[TBL] [Abstract][Full Text] [Related]
16. Engineering customized nanovaccines for enhanced cancer immunotherapy.
Guo J; Liu C; Qi Z; Qiu T; Zhang J; Yang H
Bioact Mater; 2024 Jun; 36():330-357. PubMed ID: 38496036
[TBL] [Abstract][Full Text] [Related]
17. Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy.
Wang J; Wang S; Ye T; Li F; Gao X; Wang Y; Ye P; Qing S; Wang C; Yue H; Wu J; Wei W; Ma G
Adv Sci (Weinh); 2020 Oct; 7(19):2001108. PubMed ID: 33042743
[TBL] [Abstract][Full Text] [Related]
18. Nanovaccine Displaying Immunodominant T Cell Epitopes of Fibroblast Activation Protein Is Effective Against Desmoplastic Tumors.
Shin H; Kim Y; Jon S
ACS Nano; 2023 Jun; 17(11):10337-10352. PubMed ID: 37184372
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
